You are here

Share:

T cell tuning molecules that modify the immune response to cancer cells

Summary
Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seek partners to collaborate on in vitro studies to validate these potential immunomodulators and to conduct in vivo studies in a murine cancer model to determine the effects of ligands (e.g., antibodies) to the proteins on the immune response to cancer cells. Preference will be given to responses received by March 31, 2016.
NIH Reference Number
E-117-2016
Product Type
Collaboration Opportunity
This invention is available for licensing and co-development.
Description of Technology

Researchers at NIH/NICHD have identified approximately 200 proteins as candidate molecules (leads) that “fine tune” T cell receptor (TCR) signaling. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks partners to collaborate on in vitro studies to validate these potential immunomodulators and to conduct in vivo studies in a murine cancer model to determine the effects of ligands (e.g. antibodies) to the proteins to determine their effect on the immune response to cancer cells. Preference will be given to responses received by March 31, 2016.

Potential Commercial Applications

Agents that modify the immune response to cancer cells could be used in conjunction with other immunomodulators or therapeutic agents, such as vaccines

Inventor(s)

Paul Love (NICHD), J. Pinkhasov (NICHD), Z. Li (NICHD)

Development Stage
Publications

Pending

Patent Status
  • Research Material: NIH will not pursue patent prosecution for this technology
Therapeutic Area
Updated
Monday, November 20, 2017